November 16, 2017
FDA: Baxter recalls one lot of injectable amiodarone
Editor's Note
The Food and Drug Administration (FDA) on November 15 announced the recall by Baxter International (Deerfield, Illinois) of one lot of Nexterone (amiodarone HCL) 150 mg/100 mL premixed injection because of the presence of particulate matter.
The particulate matter was identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in which the Nexterone is packaged.
The recalled lot (number NC109925) was distributed between August 23 and October 2, 2017.
Posted 11/15/2017] AUDIENCE: Pharmacy, Cardiology, Risk Manager ISSUE: Baxter International announced it is voluntarily recalling one lot of Nexterone (amiodarone HCl) 150 mg/100 mL Premixed Injection - distributed between 6/23/2017 and 10/2/2017 in the United States to wholesalers/distributors and healthcare facilities - due to the potential presence of particulate matter.
Free Daily News
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
- Data support option to skip sentinel lymph node biopsy in early breast cancer
- Surveyed nurses, physicians likely to quit
- Costs drop, access expands for GLP-1 weight loss drugs
- Q&A: Perioperative immunotherapy advances for early-stage NSCLC
- Proposals close December 16: Present at the 2025 OR Manager Conference
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement